Clinical Scorecard: Identifying Drug-Associated Retinal Artery Occlusion: A Retrospective Analysis Across Multiple Countries Using Spontaneous Reporting Data
At a Glance
Category
Detail
Condition
Retinal Artery Occlusion (RAO)
Key Mechanisms
Thromboembolism originating from large arteries or the heart; association with systemic vascular events.
Target Population
Individuals exposed to systemic medications, particularly older adults and those with chronic diseases.
Care Setting
Pharmacovigilance and post-marketing safety surveillance.
Key Highlights
36 drugs identified with significant disproportionality signals for RAO.
Strong signals observed for mepivacaine, brolucizumab, and pegaptanib.
Anesthetic agents showed the shortest median time to onset of RAO.
Guideline-Based Recommendations
Diagnosis
Utilize the Medical Dictionary for Regulatory Activities (MedDRA) for coding adverse events.
Management
Systemic management of acute RAO typically involves neurologists with stroke management expertise.
Monitoring & Follow-up
Enhance clinical awareness of medications associated with RAO risk.
Risks
Pharmaceutical agents are an increasingly significant cause of RAO, alongside behavioral risk factors.
Patient & Prescribing Data
Patients receiving systemic medications, particularly those at risk for thromboembolic events.
No proven specific ocular therapies exist for RAO; proactive management is crucial.
Clinical Best Practices
Conduct comprehensive evaluations of medications associated with RAO risk.
Utilize pharmacovigilance data to inform clinical decision-making.
